Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mexidol in primary open-angle glaucoma
NCT06903156Phase 2Completed
- Sponsor
- Pharmasoft
- Start
- Nov 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of emoxypine in primary open-angle glaucoma (POAG) (3 arms), sponsored by Pharmasoft. Primary endpoint: Mean Deviation in Static Automated Perimetry at 104 days. Started Nov 2021; status: completed.
02
Drugs
emoxypine
03
Conditions
primary open-angle glaucoma (POAG)
Beyond the preview
Go deeper on NCT06903156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06903156.